Endogenous and exogenous digoxin-like immunoreactive substances: Impact on therapeutic drug monitoring of digoxin

American Journal of Clinical Pathology

Volumn 118, Issue 1, 2002, Pages 132-140

  Dasgupta, Amitava ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Chinese medicines; Digoxin; Digoxin like immunoreactive substances; DLIS; Free digoxin; Spironolactone

Indexed keywords

BILE ACID; BILE SALT; CANRENOATE POTASSIUM; CANRENONE; DIGITALIS LIKE FACTOR; DIGOXIN; DIGOXIN ANTIBODY; FATTY ACID; LYSOPHOSPHOLIPID; PHOSPHOLIPID; SPIRONOLACTONE; STEROID;

ARTICLE; BODY FLUID; CHINESE MEDICINE; CROSS REACTION; DIGOXIN BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG PROTEIN BINDING; ESSENTIAL HYPERTENSION; HUMAN; LIVER DISEASE; PREECLAMPSIA; PRIORITY JOURNAL; UREMIA;

CARDENOLIDES; CROSS REACTIONS; DIGOXIN; DRUG MONITORING; DRUGS, CHINESE HERBAL; HUMANS; IMMUNOASSAY; SAPONINS; SPIRONOLACTONE;

EID: 0036306328     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/3VNP-TWFQ-HT9A-1QH8     Document Type: Article

References (86)

1. Endogenous digitalis-like substances in plasma of volume expanded dogs
2. Anomalous serum digoxin concentration in uremia
3. Digoxin-like immunoreactivity in normal human plasma and urine as detected by a solid phase radioimmunoassay
4. Digoxin-like immunoreactivity detected in cerebrospinal fluid of humans with fever
5. Digoxin-like immuno-reactivity in plasma and saliva of pregnant women
6. Digoxin-like immunoreactivity in renal transplant patients
7. False-positive serum digoxin concentrations determined by three digoxin assays in patients with liver disease
8. Comparison of free digoxin and total digoxin: Extent of interference from digoxinlike immunoreactive substances (DLIS) in a fluorescence polarization assay
9. Bufalin radioimmunoassays: In search of the endogenous digitalis-like substances
10. Detection of endogenous digitalis-like immunoreactive factors in human blood
11. Two novel endogenous digoxin-like immunoreactive substances isolated from human plasma ultrafiltrate
12. Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissue
13. An update on digoxin
14. Partial characterization of endogenous digoxinlike substances in human urine
15. Digoxin-like immuno-reactivity: Occurrence in three molecular forms and partial characterization
16. Falsely raised plasma digoxin concentrations in liver disease
17. Endogenous digoxinlike substances in patients with combined hepatic and renal failure
18. The possible role of digitalislike factors in pregnancy-induced hypertension
19. Endogenous digitalislike compounds: A tentative update of chemical and biological studies
20. Endogenous digoxinlike immunoreactivity in congestive heart failure
21. Hypertension and a digoxin-like substance in the plasma of dialysis patients: Possible marker for a natriuretic hormone
22. Digoxin-like immunoreactive substances in the plasma of intensive care unit patients: Relationship to organ dysfunction
23. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180
24. Effects of digoxinlike immunoreactive substances and digoxin FAB antibodies on the new digoxin microparticle enzyme immunoassay
25. Endogenous digoxin-immunoreactivite substance in normal and preeclamptic pregnancies
26. Unexplained increase in serum digoxin: A case report
27. Serum digoxin-like immunoreactive factor in children and its relation to sodium metabolism
28. Plasma and cerebrospinal fluid endogenous digoxin-like immunoreactivity in patients with aneurysmal subarachnoid haemorrhage
29. Atrial natriuretic factor and digoxin-like immunoreactive factors in diabetic patients: Their interrelation and influence of the automatic nervous system
30. Endogenous digoxin-like immunoreactive factor (DLIF) serum concentrations are decreased in manic bipolar patients compared to normal controls
31. Postmortem digoxin-like immunoreactive substances (DLIS) in patients not treated with digoxin
32. Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy
33. Endogenous digoxin-like substances in liver failure
34. Endogenous digoxin-like factors in acute myocardial infarction
35. Digoxin-like immunoreactive substances in urine of patients with mucocutaneous lymph node syndrome (MCLS)
36. Volume sensitive hypertension and the digoxin-like factor: Reversal by a Fab directed against digoxin in DOCA-salt hypertensive rats
37. Recent progress of an endogenous digitalislike factor in hypertension
38. Monitoring free digoxin instead of total digoxin in patients with congestive heart failure and high concentrations of digoxinlike immunoreactive substances
39. Digoxin-like immunoreactive substance and sodium-potassium adenosine triphosphate inhibition in normal pregnancy: A longitudinal study
40. Interference of digoxin-like immunoreactive substances with TDx digoxin II assay in different patients
41. Characterization of a urinary bufodienolide Na+,K+-ATPase inhibitor in patients after acute myocardial infarction
42. Comparison of four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors
43. Vitros digoxin immunoassay evaluated for interference by digoxin-like immunoreactive factors
44. Assessment of the immunoreactivity of digoxin metabolites and the cross-reactivity with digoxin-like immunoreactive factors in the Roche-TDM online digoxin assay
45. Interference of digoxinlike immunoreactive substances with four recent reagents for digoxin determination
46. Enzyme-multiplied immunoassay (EMIT 2000) digoxin assay compared with fluorescence polarization immunoassay and Amerlex 1251-radioimmunoassay at two Australian centers
47. Unexpected suppression of digoxin values caused by DLIF
48. Suppression of total digoxin concentration by digoxin-like immunoreactive substances in the MEIA digoxin assay: Elimination of interference by monitoring free digoxin concentrations
49. Protein binding of endogenous digoxinlike immunoreactive factors in human serum and its variation with clinical condition
50. Digoxin-like immunoreactivity eliminated from serum by centrifugal ultrafiltration before fluorescence polarization immunoassay of digoxin
51. Estimating concentration of total digoxin and digoxin-like immunoreactive substances in volume expanded patients being treated with digoxin
52. Estimating concentrations of serum total digoxin and digoxin-like immunoreactive substances in patients of cardiac failure with renal insufficiency
53. Demonstration of the presence of digoxin-like immunoreactive substance (DLIS) in the serum and urine in children with nephrotic syndrome
54. Digoxin-like immunoreactive factors in rat plasma: Effect on sodium and calcium intake
55. Natriuretic effect of digoxin-like immunoreactive substance on dog kidney
56. Antidigoxin antibodies and eclampsia
57. Circulating digoxin-like immunoreactivity in renal hypertensive rabbits: Lack of modulation by alteration in dietary sodium intake
58. Endogenous digoxinlike material in normotensive and hypertensive strains of rats
59. A study of lipid effects on the digoxin immunoassay and on the binding to and activity of Na/K-ATPase
60. Mass spectrometry studies of a novel digoxin-like substance (DLIS-2) isolated from human plasma ultrafiltrate
61. Plasma conjugated androgens in a dialysis-dependent male as immunoreactive digitalis-like factors
62. Isolation of digoxinlike immunoreactive factors from mammalian adrenal cortex
63. Isolation and characterization of a digoxin-like immunoreactive substance from human urine by affinity chromatography
64. Deglycosylated products of endogenous digoxin-like immunoreactive factor in mammalian tissue
65. The effect of spironolactone and canrenone on the digoxin radioimmunoassay
66. The influence of intravenous canrenoate on the determination of digoxin in serum by radio- and enzyme-immunoassay
67. Spironolactone-associated digoxin radioimmunoassay interference
68. The effect of renal and hepatic impairment and of spironolactone on serum digoxin assay
69. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin assays
70. Influence of spironolactone and its metabolite canrenone on serum digoxin assays
71. Cross-reactivity of TDX and OPUS immunoassay systems for serum digoxin determination
72. Intoxication due to negative canrenone interference in digoxin drug monitoring
73. Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation, liu-shen-wan, by liquid chromatography
74. Examination for toxicity of a Chinese drug, the toad glandular secretion product Chan Su, in pregnant mice and embryos
75. Pharmacology and toxicology of toad venom
76. Pharmacological actions of "kyushin," a drug containing toad venom: Cardiotonic and arrhythmogenic effects and excitatory effect on respiration
77. Effect of three sodium-potassium adenosine triphosphate inhibitors
78. Digoxin concentration in blood
79. Bufalin and unidentified substances in traditional Chinese medicine cross-react in commercial digoxin assay
80. Lethal ingestion of Chinese tea containing Chan SU
81. Positive and negative interference of the Chinese medicine Chan Su in serum digoxin measurement: Elimination of interference using a monoclonal chemiluminescent digoxin assay or monitoring free digoxin concentration
82. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng
83. Protective effects of danshen during myocardial ischemia and reperfusion: An isolated rat heart study
84. Isolation and bioactivity of new tanshinones
85. In vivo digoxin-like immunoreactivity in mice and interference of Chinese medicine danshen in serum digoxin measurement: Elimination of interference by using a chemiluminescent assay
86. Positive and negative in vitro interference of Chinese medicine Dan Shen in serum digoxin measurement: Elimination of interference by monitoring free digoxin concentration